Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

August 23, 2013

Study Completion Date

June 10, 2015

Conditions
Multiple Sclerosis
Interventions
DRUG

Ofatumumab 3mg

3mg of investigational product

DRUG

Ofatumumab 30mg

30mg of investigational product

DRUG

Ofatumumab 60mg

60mg of investigational product

DRUG

Placebo

Placebo

Trial Locations (61)

1000

GSK Investigational Site, Sofia

1113

GSK Investigational Site, Sofia

1309

GSK Investigational Site, Sofia

1431

GSK Investigational Site, Sofia

2100

GSK Investigational Site, Koebenhavn Ø

2317

GSK Investigational Site, Hamar

10961

GSK Investigational Site, Berlin

12004

GSK Investigational Site, Castellon

12163

GSK Investigational Site, Berlin

14001

GSK Investigational Site, Córdoba

17007

GSK Investigational Site, Girona

19107

GSK Investigational Site, Philadelphia

22087

GSK Investigational Site, Hamburg

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28832

GSK Investigational Site, Achim

29010

GSK Investigational Site, Málaga

30327

GSK Investigational Site, Atlanta

30625

GSK Investigational Site, Hanover

33136

GSK Investigational Site, Miami

33351

GSK Investigational Site, Sunrise

33407

GSK Investigational Site, West Palm Beach

33612

GSK Investigational Site, Tampa

35058

GSK Investigational Site, Cullman

37134

GSK Investigational Site, Verona

37204

GSK Investigational Site, Nashville

41071

GSK Investigational Site, Seville

41126

GSK Investigational Site, Modena

44791

GSK Investigational Site, Bochum

46805

GSK Investigational Site, Fort Wayne

48903

GSK Investigational Site, Baracaldo/Vizcaya

49503

GSK Investigational Site, Grand Rapids

50935

GSK Investigational Site, Cologne

60062

GSK Investigational Site, Northbrook

63755

GSK Investigational Site, Alzenau in Unterfranken

73104

GSK Investigational Site, Oklahoma City

78681

GSK Investigational Site, Round Rock

92835

GSK Investigational Site, Fullerton

98122

GSK Investigational Site, Seattle

107150

GSK Investigational Site, Moscow

119049

GSK Investigational Site, Moscow

127018

GSK Investigational Site, Moscow

194291

GSK Investigational Site, Saint Petersburg

197022

GSK Investigational Site, Saint Petersburg

214018

GSK Investigational Site, Smolensk

420021

GSK Investigational Site, Kazan'

603126

GSK Investigational Site, Nizhny Novgorod

06824

GSK Investigational Site, Fairfield

T6G 1Z1

GSK Investigational Site, Edmonton

H3A 2B4

GSK Investigational Site, Montreal

625 00

GSK Investigational Site, Brno

656 91

GSK Investigational Site, Brno

586 33

GSK Investigational Site, Jihlava

775 20

GSK Investigational Site, Olomouc

415 29

GSK Investigational Site, Teplice

04103

GSK Investigational Site, Leipzig

6162 BG

GSK Investigational Site, Sittard-geleen

5801 CE

GSK Investigational Site, Venray

08035

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01457924 - Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter